KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Gains from Sales and Divestitures (2015 - 2017)

BeOne Medicines (ONC) reported Gains from Sales and Divestitures of $268750.0 for Q4 2017, up 504.68% year-over-year from $44445.0 in Q4 2016, and up 504.68% on a QoQ basis from $44445.0 in Q4 2016.

BeOne Medicines (ONC) has 3 years of Gains from Sales and Divestitures data on file, last reported at $268750.0 in Q4 2017.

  • Quarterly Gains from Sales and Divestitures rose 504.68% year-over-year to $268750.0 in Q4 2017, while the trailing twelve-month figure through Dec 2017 was $268750.0 (up 504.68% YoY) and the FY2017 annual result came in at $268750.0, up 504.68% from the prior year.
  • Gains from Sales and Divestitures rose to $268750.0 in Q4 2017 per ONC's latest filing, from $44445.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $533333.0 in Q4 2015 and bottomed at $44445.0 in Q4 2016.
  • The 3-year median for Gains from Sales and Divestitures is $268750.0 (2017), against an average of $282176.0.
  • The widest annual swing landed in 2016, when Gains from Sales and Divestitures plunged 91.67%; it then jumped 504.68% in 2017.
  • Tracing ONC's Gains from Sales and Divestitures over 3 years: stood at $533333.0 in 2015, then sank by 91.67% to $44445.0 in 2016, then jumped by 504.68% to $268750.0 in 2017.
  • Per Business Quant, the three latest ONC Gains from Sales and Divestitures figures stand at $268750.0 (Q4 2017), $44445.0 (Q4 2016), and $533333.0 (Q4 2015).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn -
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn -
5 Akari Therapeutics 605.66 Bn 605.66 Bn -
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn
8 Evaxion A 65.12 Bn 65.10 Bn -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn
10 BeOne Medicines - - 1.35 Bn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2017 268,750.00
Dec 31, 2017 268,750.00
Dec 31, 2016 44,445.00
Dec 31, 2016 44,445.00
Dec 31, 2015 533,333.00
Dec 31, 2015 533,333.00